Dr Emil Kendziorra
Founder and CEO, Tomorrow.bio
Co-Founder and CEO, Tomorrow Bio; President of the Board, European Biostasis Foundation · Zurich chapter
Dr. Emil Kendziorra is co-founder and CEO of Tomorrow Bio (Berlin, 2020), a human cryopreservation provider with 1,000+ members and 20 patients preserved, and President of the Board of the European Biostasis Foundation. Physician, former cancer researcher, two startup exits (Medlanes, onFeedback).
Highlights
- Co-founded Tomorrow Bio in Berlin (2020) with Fernando Azevedo Pinheiro; the company has grown to 1,000+ signed members across 45+ countries and has cryopreserved 20 people and 10 pets.
- Raised a €5 million seed round (first close, 2025) led by Blast.Club and Truventuro, with 160+ million euros in total contract value; expanded Tomorrow Bio to the continental USA in July 2024.
- Serves as President of the Board of the European Biostasis Foundation (Switzerland), which operates the long-term patient storage facility in Rafz and funds research in biostasis, cryobiology and biopreservation.
- Founded and led two health/tech companies to acquisition: Medlanes (exit to ZAVA) and onFeedback (exit to QuestionPro).
- Graduated summa cum laude from the University of Göttingen and completed doctoral research in translational cancer research before moving into entrepreneurship.
Co-founded Tomorrow Bio in Berlin (2020) with Fernando Azevedo Pinheiro; the company has grown to 1,000+ signed members across 45+ countries and has cryopreserved 20 people and 10 pets.. Raised a €5 million seed round (first close, 2025) led by Blast.Club and Truventuro, with 160+ million euros in total contract value; expanded Tomorrow Bio to the continental USA in July 2024.. Serves as President of the Board of the European Biostasis Foundation (Switzerland), which operates the long-term patient storage facility in Rafz and funds research in biostasis, cryobiology and biopreservation.. Founded and led two health/tech companies to acquisition: Medlanes (exit to ZAVA) and onFeedback (exit to QuestionPro).. Graduated summa cum laude from the University of Göttingen and completed doctoral research in translational cancer research before moving into entrepreneurship..
About Emil Kendziorra
Dr. Emil Kendziorra graduated summa cum laude from the University of Göttingen and did several years of cancer research in the hopes of contributing to longevity science. After realizing how slowly life-extension research was progressing he made a pivot into entrepreneurship. He has been CEO of multiple tech and medical companies, most recently as a Founder and CEO of Medlanes (Exit to ZAVA) and onFeedback (Exit to QuestionPro). Emil has decided to dedicate the next decades of this life to advancing medical Biostasis and cryomedicine. Currently, he is the CEO of Tomorrow Bio and the President of the Board at the European Biostasis Foundation.
Credentials
- MDMedical degree with doctorate in translational cancer research (summa cum laude)— University of Göttingen
Education
Topics & Expertise
- Aging Biology & Senolytics
- Preventive Medicine
- human cryopreservation and cryonics
- medical biostasis
- cryoprotection and vitrification
- standby, stabilization and transport (SST) logistics
- longevity and life-extension research
- translational cancer research
- health-tech entrepreneurship
Talks at Longevity Austria
Past
- The Long Game: Zurich Health Night @Google — Mar 11, 2026 · Google, Europaallee 36, 8004 Zurich
- A talk on cryopreservation by Tomorrow.bio & Longevity Germany — Dec 2, 2025 · Munich
Frequently Asked
Who is Dr. Emil Kendziorra?
Dr. Emil Kendziorra is a German physician and entrepreneur, co-founder and CEO of Tomorrow Bio, a Berlin-based human cryopreservation company, and President of the Board of the European Biostasis Foundation in Switzerland. He graduated summa cum laude from the University of Göttingen and worked for several years in translational cancer research before founding multiple health and tech companies.
What does Emil Kendziorra's company Tomorrow Bio do?
Tomorrow Bio, founded in Berlin in 2020 by Emil Kendziorra and Fernando Azevedo Pinheiro, provides human and pet cryopreservation: after legal death, patients are stabilized, perfused with cryoprotectants, cooled to -196°C and stored long term in liquid nitrogen at a facility in Rafz, Switzerland. The company runs standby ambulance teams across Europe and the US and has over 1,000 signed members, 20 cryopreserved patients and 10 pets.
What is Emil Kendziorra's medical and research background?
Emil Kendziorra trained as a medical doctor at the University of Göttingen, graduating summa cum laude, and completed doctoral work in translational cancer research. He spent several years in cancer research hoping to contribute to life-extension science, then pivoted to entrepreneurship after concluding the field was progressing too slowly, founding Medlanes (acquired by ZAVA) and onFeedback (acquired by QuestionPro) before dedicating himself to medical biostasis.
What is the European Biostasis Foundation and what is Emil Kendziorra's role there?
The European Biostasis Foundation (EBF) is a Swiss foundation focused on translational and applied research in biostasis, cryobiology and biopreservation; it operates the long-term patient storage facility in Rafz, Switzerland used by Tomorrow Bio. Emil Kendziorra helped establish the foundation and serves as President of its Board.